Hyperthermic isolated liver perfusion with melphalan and bevacizumab;Chimio-hyperthermie sur foie isolé perfusé avec du bévacizumab et du melfalan

Journal of Visceral Surgery

Volumn 150, Issue 1, 2013, Pages 60-66

  Voron, T ^a   Zinzindohoue F ^a   Journois, D ^a   Herve C ^b   Ponzio, O ^c   Lucas, N ^d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Laboratoire d éthique médicale   (France)

^c Service de Chirurgie Digestive   (France)

^d Clinique Paris Centre   (France)

Author keywords

Bevacizumab; Hepatocellular carcinoma; Isolated liver perfusion

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; MELPHALAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; FATALITY; FEMALE; GLUCAGONOMA; HUMAN; HYPERTHERMIC THERAPY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PATHOLOGY; REGIONAL PERFUSION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FATAL OUTCOME; FEMALE; GLUCAGONOMA; HUMANS; HYPERTHERMIA, INDUCED; LIVER NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 84877055352     PISSN: 18787886     EISSN: 18787878     Source Type: Journal    
DOI: 10.1016/j.jviscsurg.2012.10.018     Document Type: Article

References (47)

1. Franco, D., Capussotti, L., Smadja, C., et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 98 (1990), 733–738.
2. Tsuzuki, T., Sugioka, A., Ueda, M., et al. Hepatic resection for hepatocellular carcinoma. Surgery 107 (1990), 511–520.
3. Hanish, S.I., Knechtle, S.J., Liver transplantation for the treatment of hepatocellular carcinoma. Oncology (Williston Park) 25 (2011), 752–757.
4. Qian, J., Interventional therapies of unresectable liver metastases. J Cancer Res Clin Oncol 137 (2011), 1763–1772.
5. Scheele, J., Stang, R., Altendorf-Hofmann, A., Paul, M., Resection of colorectal liver metastases. World J Surg 19 (1995), 59–71.
6. Yamamoto, J., Shimada, K., Kosuge, T., Yamasaki, S., Sakamoto, M., Fukuda, H., Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 86 (1999), 332–337.
7. Nordlinger, B., Guiguet, M., Vaillant, J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77 (1996), 1254–1262.
8. Sutcliffe, R., Maguire, D., Ramage, J., Rela, M., Heaton, N., Management of neuroendocrine liver metastases. Am J Surg 187 (2004), 39–46.
9. Kunzli, B.M., Abitabile, P., Maurer, C.A., Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. World J Hepatol 3 (2011), 8–14.
10. Berber, E., Pelley, R., Siperstein, A.E., Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 23 (2005), 1358–1364.
11. Solbiati, L., Livraghi, T., Goldberg, S.N., et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221 (2001), 159–166.
12. Anand, A., Anand, N., Anand, A., Re: Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst 88 (1996), 838–839.
13. Mocellin, S., Pilati, P., Lise, M., Nitti, D., Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 25 (2007), 5649–5654.
14. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009:CD007823.
15. van Iersel, L.B., Hoekman, E.J., Gelderblom, H., et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 15 (2008), 1891–1898.
16. van Iersel, L.B., Koopman, M., van de Velde, C.J., et al. Management of isolated non-resectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 21 (2010), 1662–1667.
17. Alexander, H.R. Jr., Bartlett, D.L., Libutti, S.K., et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 16 (2009), 1852–1859.
18. Zeh, H.J. 3rd, Brown, C.K., Holtzman, M.P., Egorin, M.J., Holleran, J.L., A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16 (2009), 385–394.
19. Engin, K., Biological rationale and clinical experience with hyperthermia. Control Clin Trials 17 (1996), 316–342.
20. Hahn, G.M., Li, G.C., Interactions of hyperthermia and drugs: treatments and probes. Natl Cancer Inst Monogr 61 (1982), 317–323.
21. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer, 2008, 2010.
22. Boucher, E., Corbinais, S., Brissot, P., Boudjema, K., Raoul, J.L., Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 50 (2002), 305–308.
23. Benson, A.B. 3rd, Mitchell, E., Abramson, N., Klencke, B., Ritch, P., et al. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Ann Oncol 13 (2002), 576–581.
24. Bobbio-Pallavicini, E., Porta, C., Moroni, M., et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33 (1997), 1784–1788.
25. Lai, C.L., Wu, P.C., Chan, G.C., Lok, A.S., Lin, H.J., Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62 (1988), 479–483.
26. Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
27. Salhab, M., Canelo, R., An overview of evidence-based management of hepatocellular carcinoma: A meta-analysis. J Cancer Res Ther 7 (2011), 463–475.
28. Pelletier, G., Ducreux, M., Gay, F., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial, Groupe CHC. J Hepatol 29 (1998), 129–134.
29. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256–61.
30. Pelletier, G., Roche, A., Ink, O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11 (1990), 181–184.
31. Lo, C.M., Ngan, H., Tso, W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002), 1164–1171.
32. Llovet, J.M., Real, M.I., Montana, X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002), 1734–1739.
33. Sangro, B., Rios, R., Bilbao, I., et al. Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology 62 (2002), 293–298.
34. Toyoda, H., Nakano, S., Kumada, T., et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52 (1995), 295–299.
35. Bloomston, M., Al-Saif, O., Klemanski, D., et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 11 (2007), 264–271.
36. Gupta, S., Johnson, M.M., Murthy, R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (2005), 1590–1602.
37. Kouvaraki, M.A., Ajani, J.A., Hoff, P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004), 4762–4771.
38. Kulke, M.H., Stuart, K., Enzinger, P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006), 401–406.
39. Kulke, M.H., Lenz, H.J., Meropol, N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26 (2008), 3403–3410.
40. Grover, A.C., Libutti, S.K., Pingpank, J.F., Helsabeck, C., Beresnev, T., Alexander, H.R. Jr., Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136 (2004), 1176–1182.
41. Mocellin, S., Pilati, P., Da Pian, P., et al. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Ann Surg Oncol 14 (2007), 802–809.
42. van Iersel, L.B., Gelderblom, H., Vahrmeijer, A.L., et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19 (2008), 1127–1134.
43. Christoforidis, D., Martinet, O., Lejeune, F.J., Mosimann, F., Isolated liver perfusion for non-resectable liver tumours: a review. Eur J Surg Oncol 28 (2002), 875–890.
44. Ku, Y., Iwasaki, T., Tominaga, M., et al. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg 239 (2004), 53–60.
45. van Etten, B., Brunstein, F., van, I.M.G., et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 11 (2004), 598–605.
46. Pingpank, J.F., Libutti, S.K., Chang, R., et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23 (2005), 3465–3474.
47. Verhoef, C., de Wilt, J.H., Brunstein, F., et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol 15 (2008), 1367–1374.